Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti‐TNF alpha antibodies
- 30 April 2014
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 23 (7) , 735-744
Abstract
Purpose: We aimed to analyse malignancy rates and predictors for the development of malignancies in a large German inflammatory bowel disease (IBD) cohort treated with thiopurines and/or anti‐tumour necrosis factor (TNF) antibodies.Methods: De novo malignancies in 666 thiopurine‐treated and/or anti‐TNF‐treated IBD patients were analysed. Patients (n = 262) were treated with thiopurines alone and never exposed to anti‐TNF antibodies (TP group). In addition, patients (n = 404) were exposed to anti‐TNF antibodies (TNF+ group) with no (7.4%), discontinued (80.4%) or continued (12.1%) thiopurine therapy.Results: In the TP group, 20 malignancies were observed in 18 patients compared with 8 malignancies in 7 patients in the TNF+ group (hazard ratio 4.15; 95% CI 1.82–9.44; p = 0.0007; univariate Cox regression). Moreover, 18.2% of all patients in the TP group ≥50 years of age developed a malignancy, compared with 3.8% of all patients p = 0.0008). In the TNF+ group, 6.5% of all patients ≥50 years of age developed malignancies compared with 0.3% of all patients p = 0.0007). In both groups combined, thiopurine treatment duration ≥4 years was associated with the risk for skin cancer (p = 0.0024) and lymphoma (p = 0.0005).Conclusions: Our data demonstrate an increased risk for the development of malignancies in IBD patients treated with thiopurines in comparison with patients treated with anti‐TNF antibodies with or without thiopurines. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG, BE 4490/2-1, DFG, BR 1912/6-1)
- Else Kröner-Fresenius-Stiftung (2010_EKES.32)
This publication has 46 references indexed in Scilit:
- T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH StudyAmerican Journal of Gastroenterology, 2013
- A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2012
- Nonmelanoma skin cancer in inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Relapse Rate Following Azathioprine Withdrawal in Maintaining Remission for Crohn’s Disease: A Meta-AnalysisDigestive Diseases and Sciences, 2011
- Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infectionsAlimentary Pharmacology & Therapeutics, 2009
- Cancer risks in Crohn disease patientsAnnals of Oncology, 2008
- Serious Events with Infliximab in Patients with Inflammatory Bowel DiseaseDrug Safety, 2008
- EFFECTS OF IMMUNOSUPPRESSIVE THERAPY ON THE INDUCTION OF SKIN TUMORS BY ULTRAVIOLET IRRADIATION IN HAIRLESS MICETransplantation, 1987
- EFFECT OF IMMUNOSUPPRESSIVE AGENTS AND SUNSCREENS ON UV CARCINOGENESIS IN THE HAIRLESS MOUSEImmunology & Cell Biology, 1985
- Chronic toxicity of azathioprine and the effect of this immunosuppressant on liver tumor induction by the carcinogen N-hydroxy-N-2-fluorenylacetamideToxicology and Applied Pharmacology, 1970